219 related articles for article (PubMed ID: 31785443)
21. Deuterium Tetrabenazine for Tardive Dyskinesia.
Cummings MA; Proctor GJ; Stahl SM
Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
[TBL] [Abstract][Full Text] [Related]
22. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
24. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
25. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
26. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
27. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
28. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
29. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
Correll CU; Cutler AJ; Kane JM; McEvoy JP; Liang GS; O'Brien CF
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30695293
[TBL] [Abstract][Full Text] [Related]
30. Tardive Dyskinesia: Treatment Update.
Arya D; Khan T; Margolius AJ; Fernandez HH
Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
[TBL] [Abstract][Full Text] [Related]
31. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
Citrome L; Saklad SR
J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
[TBL] [Abstract][Full Text] [Related]
32. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
McEvoy JP
J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
[TBL] [Abstract][Full Text] [Related]
33. Deutetrabenazine in the treatment of tardive dyskinesia.
Niemann N; Jimenez-Shahed J
Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
[TBL] [Abstract][Full Text] [Related]
34. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
[TBL] [Abstract][Full Text] [Related]
35. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
[TBL] [Abstract][Full Text] [Related]
36. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
Kim AP; Baker DE; Levien TL
Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
[TBL] [Abstract][Full Text] [Related]
37. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
[TBL] [Abstract][Full Text] [Related]
38. Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms.
Lindenmayer JP; Burke E; Tsuboyama G; Chahal Y; Grewal HK
J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):109-111. PubMed ID: 34668876
[No Abstract] [Full Text] [Related]
39. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
[TBL] [Abstract][Full Text] [Related]
40. Valbenazine and Deutetrabenazine as possible treatments for neuroleptic-induced supersensitivity psychosis and antipsychotic dependence.
Skaff R
CNS Spectr; 2019 Aug; 24(4):352-353. PubMed ID: 30458899
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
